王朝晖, 罗丰, 刘小楣. PPARγ激活剂罗格列酮对兔动脉粥样硬化斑块消退的影响J. 药学学报, 2005, 40(11): 1051-1053.
引用本文: 王朝晖, 罗丰, 刘小楣. PPARγ激活剂罗格列酮对兔动脉粥样硬化斑块消退的影响J. 药学学报, 2005, 40(11): 1051-1053.
WANG Zhao-hui, LUO Feng, LIU Xiao-mei. Effect of PPARγ agonist rosiglitazone on regression of the atherosclerotic plaques in rabbitsJ. Acta Pharmaceutica Sinica, 2005, 40(11): 1051-1053.
Citation: WANG Zhao-hui, LUO Feng, LIU Xiao-mei. Effect of PPARγ agonist rosiglitazone on regression of the atherosclerotic plaques in rabbitsJ. Acta Pharmaceutica Sinica, 2005, 40(11): 1051-1053.

PPARγ激活剂罗格列酮对兔动脉粥样硬化斑块消退的影响

Effect of PPARγ agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits

  • Abstract: AimTo explore the prevention of atherosclerosis by PPARγ agonist rosiglitazone. Methods24 male New Zealand white rabbits weighing 1.8 to 2.2 kg were randomly divided into 3 groups: control group, normal rabbit chow; cholesterol group,1% cholesterol diet; rosiglitazone group, 1% cholesterol diet supplemented with rosiglitazone 0.5 mg·kg-1·d-1 for 6 weeks. Rabbits in cholesterol group and rosiglitazone group were sequentially fed 1% cholesterol-containing diet for 16 weeks. At the end of the experiment, blood glucose, serum lipids levels, ratio of plaque area to aorta area and ratio of intima to media were determined. ResultsHypercholesterolemia was successfully reproduced in rabbits. Adnimistration of rosiglitazone significantly decreased serum TC and LDL-C. The ratio of intima to media and ratio of plaque area to aorta area were also reduced. ConclusionRosiglitazone could prevent atherosclerosis by decreasing levels of TC and LDL-C.

     

/

返回文章
返回